Skip to main content
SpringerLink
Log in

ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

    Daniel W. Kim MD, MBA, Grace Lee MD, Theodore S. Hong MD, Florence K. Keane MD, Lorraine C. Drapek DNP & Jennifer Y. Wo MD

  2. Harvard Medical School, Boston, MA, USA

    Grace Lee MD

  3. Massachusetts General Hospital Biostatistics Center, Boston, MA, USA

    Nora K. Horick MS

  4. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

    Guichao Li MD, Christine Eyler MD, PhD & Jennifer Y. Wo MD

  5. Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA

    Eric Roeland MD, David P. Ryan MD, Jill N. Allen MD, Aparna R. Parikh MD, MS, Sam Klempner MD & Jeffrey W. Clark MD, PhD

  6. Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

    David Berger MD & John T. Mullen MD

Authors
  1. Daniel W. Kim MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grace Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Theodore S. Hong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guichao Li MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nora K. Horick MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eric Roeland MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Florence K. Keane MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christine Eyler MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lorraine C. Drapek DNP
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David P. Ryan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jill N. Allen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. David Berger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Aparna R. Parikh MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. John T. Mullen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Sam Klempner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Jeffrey W. Clark MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Jennifer Y. Wo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Y. Wo MD.

Ethics declarations

T.S.H. has served as a compensated consultant for Merck, Novocure, and Synthetic Biologics and serves as research support for Ipsen, BMS, Astra-Zeneca, Taiho, IntraOp, and Tesaro (GlaxoSmithKline). S.J.K. has served as a compensated consultant for Merck, BMS, Eli Lilly, Natera, Astellas, Daiichi Sankyo, and Pieris Oncology and owns stock/equity in Turning Point Therapeutics, Inc. A.R.P. has received personal fees from Checkmate Pharma, Eli Lilly, Pfizer, Roche, C2I genomics, Research to Institution Puretech, PMV Pharma, Plexxicon, Takeda, BMS, and Novartis. D.P.R. owns equity in Exact Sciences and Acworth Pharmaceuticals, has a grant in SU2C, and serves as a publisher for Uptodate.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, D.W., Lee, G., Hong, T.S. et al. ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. Ann Surg Oncol 28 (Suppl 3), 690–691 (2021). https://doi.org/10.1245/s10434-021-10753-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10753-0

Search

Navigation